To explore the experience, roles, responsibilities, perceptions, challenges and expectations of stakeholders on Post-Trial Access (PTA) during epidemic/pandemic

Post-trial arrangement [PTA] or post-trial access [PTA] refers to making the intervention that has been studied in the clinical trial/s especially by the pharmaceutical industry available to those who took part in the study or a wider population from which the study participants were drawn. PTA includes many stakeholders and they are - Pharmaceutical Sponsors, investigators and researchers, policy makers, governments, and even trade associations. to include communities, policy makers, governments, and trade associations. Guidelines on PTA are limited especially in LMICs and this study hopes to address this gap. It has been envisaged with the broad aim of understanding how PTA works [or otherwise] in LMICs through qualitative research. The study essentially will use questionnaires to interview the multiple stakeholders listed now either as one on one discussions or focused group discussions. Whatever comes out from these interviews will be “coded” to find “themes” meaning what really do all these stakeholders feel about PTA.